journal
MENU ▼
Read by QxMD icon Read
search

Neurology and Therapy

journal
https://www.readbyqxmd.com/read/28316064/depression-among-hiv-aids-patients-on-highly-active-antiretroviral-therapy-in-the-southwest-regional-hospitals-of-cameroon-a-cross-sectional-study
#1
Pleasure Atoh Ngum, Peter Nde Fon, Roland Cheofor Ngu, Vincent Siysi Verla, Henri Namme Luma
INTRODUCTION: HIV patients are now having longer life expectancies with the use of antiretroviral therapy (ART). However, the issue of mental illness has surfaced with depression being the most common in these patients, which has markedly reduced patient adherence to ART. In Cameroon, the management of HIV/AIDS does not incorporate psychiatric manifestations and depression is therefore underdiagnosed. The aim of our study was to determine the prevalence and determinants of depressive symptoms and their association with adherence to ART among HIV/AIDS patients on HAART in the Southwest Regional Hospitals of Cameroon...
March 18, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28211024/comparative-effectiveness-research-of-disease-modifying-therapies-for-the-management-of-multiple-sclerosis-analysis-of-a-large-health-insurance-claims-database
#2
Aaron Boster, Jacqueline Nicholas, Ning Wu, Wei-Shi Yeh, Monica Fay, Michael Edwards, Ming-Yi Huang, Andrew Lee
INTRODUCTION: Limited data are available on the real-world effectiveness of newer oral disease-modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to retrospectively compare the real-world effectiveness of dimethyl fumarate (DMF), fingolimod, teriflunomide, and injectable DMTs in routine clinical practice based on US claims data. METHODS: Patients newly-initiating DMF, interferon beta (IFNβ), glatiramer acetate (GA), teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial Claims Databases (N = 6372)...
February 16, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28176189/number-needed-to-treat-in-multiple-sclerosis-clinical-trials
#3
REVIEW
Macaulay Okwuokenye, Annie Zhang, Amy Pace, Karl E Peace
Clinicians are expected to select a therapy based on their appraisal of evidence on benefit-to-risk profiles of therapies. In the management of relapsing-remitting multiple sclerosis (RRMS), evidence is typically expressed in terms of risk (proportion) of event, risk reduction, relative and hazard rate reduction, or relative reduction in the mean number of magnetic resonance imaging lesions. Interpreting treatment effect using these measures from a RRMS clinical trial is fairly reliable; however, this might not be the case when treatment effect is expressed in terms of the number needed to treat (NNT)...
February 7, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28093681/quantifying-the-benefits-of-dimethyl-fumarate-over-%C3%AE-interferon-and-glatiramer-acetate-therapies-on-work-productivity-outcomes-in-ms-patients
#4
Andrew Lee, James Pike, Michael R Edwards, Jennifer Petrillo, John Waller, Eddie Jones
INTRODUCTION: Dimethyl fumarate (DMF) is a novel oral therapy used for the treatment of relapse-remitting multiple sclerosis (RRMS). In two 2-year pivotal Phase 3 trials in patients with RRMS, DMF significantly reduced disease activity based on both clinical and magnetic resonance imaging (MRI) findings and demonstrated an acceptable safety profile. However, there is currently a lack of comparative data which explore the relationship between work productivity and health-related quality of life (HRQoL) outcomes in RRMS and how these differ among RRMS therapies, including DMF...
January 16, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28078634/natalizumab-for-achieving-relapse-free-t1-gadolinium-enhancing-lesion-free-and-t2-lesion-free-status-in-japanese-multiple-sclerosis-patients-a-phase-2-trial-subanalysis
#5
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Nobuhisa Ohtsuka, Qunming Dong, J T Tibung
INTRODUCTION: In a phase 2 trial of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis (RRMS), treatment-related changes in relapses, brain lesions, and disability worsening were found to be comparable with those observed in the phase 3 studies of natalizumab in primarily non-Asian RRMS patients. METHODS: This subanalysis of the placebo-controlled phase 2 trial of natalizumab in Japanese RRMS patients (n = 94) evaluated the effects of natalizumab versus placebo on the proportion of patients who achieved relapse-free, T1 gadolinium-enhancing (Gd+) lesion-free, and new/newly enlarged T2 lesion-free status, defined as "no evidence of inflammatory disease activity" (NEDA)-like status, after 24 weeks of treatment...
January 11, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28054240/risk-of-adverse-outcomes-for-older-people-with-dementia-prescribed-antipsychotic-medication-a-population-based-e-cohort-study
#6
Michael Dennis, Laura Shine, Ann John, Amanda Marchant, Joanna McGregor, Ronan A Lyons, Sinead Brophy
INTRODUCTION: Over recent years there has been growing evidence of increased risk of mortality associated with antipsychotic use in older people with dementia. Although this concern combined with limited evidence of efficacy has informed guidelines restricting antipsychotic prescription in this population, the use of antipsycotics remains common. Many published studies only report short-term outcomes, are restricted to examining mortality and stroke risk or have other limitations. The aim of this study was to assess adverse outcomes associated with the use of antipsychotics in older people living with dementia in Wales (UK)...
January 4, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/27921221/safety-and-efficacy-of-natalizumab-in-japanese-patients-with-relapsing-remitting-multiple-sclerosis-open-label-extension-study-of-a-phase-2-trial
#7
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Nobuhisa Ohtsuka, Yan Ling, Shinichi Torii, Nisha Lucas, Geoffrey Kuesters, Deb Steiner, J T Tibung
INTRODUCTION: The efficacy of natalizumab was evaluated in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) in a 24-week, phase 2 bridging study. An open-label, 2-year extension study from this trial was conducted to assess the safety and efficacy of natalizumab treatment in Japanese patients. METHODS: A total of 97 patients (43 previously on placebo; 54 previously on natalizumab) who had completed the bridging study were treated with 300 mg natalizumab every 4 weeks...
December 5, 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27915429/high-risk-pml-patients-switching-from-natalizumab-to-alemtuzumab-an-observational-study
#8
Simona Malucchi, Marco Capobianco, Marianna Lo Re, Maria Malentacchi, Alessia di Sapio, Manuela Matta, Francesca Sperli, Antonio Bertolotto
INTRODUCTION: The choice of therapy in patients withdrawing from natalizumab treatment is still an open question and neurologists need strategies to manage this group of patients. The aim of this study is to evaluate if alemtuzumab is able to control the disease when used in patient who have stopped natalizumab. METHODS: 16 patients stopped natalizumab treatment after a median number of 20 infusions (range 12-114); all the patients were responders to natalizumab (neither clinical nor radiological activity during natalizumab therapy) and the reason for stopping was the risk of PML for all of them...
December 3, 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27830535/editorial-introduction
#9
EDITORIAL
Marwan N Sabbagh
No abstract text is available yet for this article.
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27778193/evaluation-of-quality-of-life-in-patients-with-narcolepsy-treated-with-sodium-oxybate-use-of-the-36-item-short-form-health-survey-in-a-clinical-trial
#10
Richard Bogan, Todd Swick, Mortimer Mamelak, Ruzica Kovacevic-Ristanovic, Chinglin Lai, Jed Black, Kathleen F Villa, Jacques Montplaisir
INTRODUCTION: The present post hoc analysis was designed to evaluate health-related quality of life (HRQoL) using the 36-item Short Form Health Status Survey (SF-36) during an 8-week trial of sodium oxybate (SXB). METHODS: SF-36 was assessed in a phase 3 placebo-controlled trial in patients with narcolepsy (N = 228) randomized to placebo or SXB in doses of 4.5, 6, or 9 g nightly for 8 weeks. Changes from baseline in SF-36 (last observation carried forward) were compared between SXB and placebo, and effect sizes (ES) were estimated...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27744504/the-effect-of-dimethyl-fumarate-on-cerebral-gray-matter-atrophy-in-multiple-sclerosis
#11
Sheena L Dupuy, Shahamat Tauhid, Shelley Hurwitz, Renxin Chu, Fawad Yousuf, Rohit Bakshi
INTRODUCTION: The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing-remitting (RR) MS. METHODS: We retrospectively analyzed 20 patients with RRMS at the start of DMF [age (mean ± SD) 46.1 ± 10.2 years, Expanded Disability Status Scale (EDSS) score 1...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27640189/multiple-sclerosis-in-pediatrics-current-concepts-and-treatment-options
#12
REVIEW
Jasna Jancic, Blazo Nikolic, Nikola Ivancevic, Vesna Djuric, Ivan Zaletel, Dejan Stevanovic, Sasa Peric, John N van den Anker, Janko Samardzic
Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system. MS is increasingly recognized in the pediatric population, and it is usually diagnosed around 15 years of age. The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial disease. The disease in children almost always presents in the relapsing-remittent form. The therapy involves treatment of relapses, and immunomodulatory and symptomatic treatment...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27624575/cardiac-safety-profile-of-first-dose-of-fingolimod-for-relapsing-remitting-multiple-sclerosis-in-real-world-settings-data-from-a-german-prospective-multi-center-observational-study
#13
Ralf A Linker, Guillaume Wendt
INTRODUCTION: Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomatic self-limited atrioventricular (AV) blocks. This German non-interventional clinical study aimed to assess the cardiac safety profile in RRMS patients during at least 6 h after the initial treatment or restart after interruption of fingolimod in real-world settings...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27553839/current-data-on-and-clinical-insights-into-the-treatment-of-first-episode-nonaffective-psychosis-a-comprehensive-review
#14
REVIEW
Benedicto Crespo-Facorro, Jose Maria Pelayo-Teran, Jacqueline Mayoral-van Son
Implementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a first episode of psychosis (FEP) is a complex and crucial task, with relevant impact in illness outcome. Treatment approaches in the early stages should go beyond choosing the right antipsychotic drug and should also address tractable factors influencing the risk of relapse. Effectiveness and likely metabolic and endocrine disturbances differ among second-generation antipsychotics (SGAs) and should guide the choice of the first-line treatment...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27506698/priority-of-treatment-outcomes-for-caregivers-and-patients-with-mild-cognitive-impairment-preliminary-analyses
#15
Polaris González Barrios, Ricardo Pabón González, Sherrie M Hanna, Angela M Lunde, Julie A Fields, Dona E C Locke, Glenn E Smith
INTRODUCTION: The patient-centered movement advocates for greater attention to the outcomes that matter most to patients and their families. In neurodegenerative disease, determination of patient and caregiver priorities has received scant attention in part because dementia patients are deemed unreliable reporters. However, people with mild cognitive impairment (MCI) likely retain capacity to report their preferences. METHODS: In two separate MCI cohorts, we conducted preliminary analyses of patient and caregiver priorities among seven patient and five caregiver outcomes of the HABIT(®) Healthy Action to Benefit Independence & Thinking program (Mayo Clinic, Rochester, MN, USA)...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27411694/pregnancy-experience-nonclinical-studies-and-pregnancy-outcomes-in-the-daclizumab-clinical-study-program
#16
Ralf Gold, Dusan Stefoski, Krzysztof Selmaj, Eva Havrdova, Christopher Hurst, Joan Holman, Belen Tornesi, Surekha Akella, Peter McCroskery
INTRODUCTION: Multiple sclerosis (MS) is more common in women and can occur during childbearing years; thus, information on outcomes following exposure to MS therapy during pregnancy is important. No formal studies of daclizumab have been conducted in pregnant women. Here, we report available nonclinical and clinical data on pregnancy outcomes from the daclizumab clinical study program. METHODS: Reproductive and developmental toxicity studies were conducted in cynomolgus monkeys...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27283293/cost-of-treatment-of-cerebral-aneurysm-embolization-study-of-associated-factors
#17
Amine Cheikh, Razine Rachid, Aasfara Jehanne, Ababou Adil, Benomar Ali, Yahya Cherrah, El Hassani Amine, El Quessar Abdeljalil
BACKGROUND: Surgical clipping or endovascular coiling are the main procedures used in the treatment of cerebral aneurysms, with a preference for endovascular coiling. In Morocco, the number of patients needing endovascular coiling is growing, but many of them do not have access to this technique. The aim of this study was to determine the main parameters associated with variations in the total cost of this procedure in order to establish the amount (lump sum) that may be reimbursed by health insurance funds...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27277705/survey-of-us-patients-with-multiple-sclerosis-comparison-of-the-new-electronic-interferon-beta-1b-autoinjector-betaconnect%C3%A2-with-mechanical-autoinjectors
#18
Donald A Barone, Barry A Singer, Lubo Merkov, Mark Rametta, Gustavo Suarez
INTRODUCTION: Patients with multiple sclerosis (MS) generally undergo long-term treatment with disease-modifying therapies (DMTs). In the US, patients taking glatiramer acetate, interferon beta-1a, or interferon beta-1b, typically use a mechanical autoinjector. Recent survey results have shown that using an electronic autoinjector, such as BETACONNECT™ (Bayer Pharma AG) for interferon beta-1b/Betaseron(®) (Bayer Pharma AG) may reduce injection discomfort and increase patient satisfaction with treatment...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27896785/prescription-patterns-of-medications-for-alzheimer-s-disease-in-japan-from-2010-to-2015-a-descriptive-pharmacy-claims-database-study
#19
Kimiko Kadohara, Izumi Sato, Yuko Doi, Masaru Arai, Yosuke Fujii, Toshiyuki Matsunaga, Koji Kawakami
INTRODUCTION: Although four kinds of Alzheimer's disease (AD) drugs are available at present there was only one drug until 2011 in Japan. This study aimed to elucidate prescription trends of these medications for AD in Japanese outpatients before and after the new drug releases in 2011. METHODS: This descriptive study of pharmacy claims databases analyzed outpatient prescription data from community pharmacies across Japan. The study patients were 20 years or older and first administered medications for AD (donepezil, memantine, rivastigmine, or galantamine) between January 2010 and September 2014...
November 28, 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27878522/informal-care-time-and-cost-in-a-large-clinical-trial-sample-of-patients-with-mild-to-moderate-alzheimer-s-disease-determinants-and-level-of-change-observed
#20
Loretto Lacey, Joel Bobula, Timothy Niecko, Christopher Leibman
INTRODUCTION: We evaluate the association between caregiver (informal) time/cost and illness severity from two recently completed clinical trials of an investigational drug for Alzheimer's disease (AD). METHODS: Changes from baseline caregiver time were calculated and treatment effects analyzed using a restricted maximum likelihood-based mixed model for repeated measures. Four separate models were then estimated to examine the association between caregiver time costs and the clinical endpoints measured during the trials, including cognition (MMSE), function (DAD), behavior (NPI), global disability (CDR) and dependence (DS)...
November 22, 2016: Neurology and Therapy
journal
journal
49896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"